Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932982 | 0.88 | ITGB1 (0.51) | ITGB1ITGA4 | |
| SCHEMBL2058655 | 0.83 | ITGB1 (0.49) | LMNATSHRC5AR1MMP9CA12 | |
| SCHEMBL2058768 | 0.78 | ITGB1 (0.50) | LMNATSHRC5AR1MMP9ITGB1 | |
| SCHEMBL2058944 | 0.72 | ITGB1 (0.63) | ITGB1ITGA4 | |
| SCHEMBL5572244 | 0.71 | HSD17B10 (0.52) | LMNAALDH1A1TDP1POLBADAMTS4 | |
| SCHEMBL5569735 | 0.71 | HSD17B10 (0.52) | LMNAALDH1A1TDP1POLBADAMTS4 | |
| SCHEMBL3936177 | 0.71 | ITGB1 (0.55) | ITGB1ITGA4 | |
| SCHEMBL5850973 | 0.71 | CA1 (0.51) | MMP9ALDH1A1CA12CA9CA1 | |
| SCHEMBL5572753 | 0.70 | SMN1; SMN2 (0.55) | LMNAMMP9ALDH1A1CA12CA9 | |
| SCHEMBL5496683 | 0.70 | LMNA (0.61) | LMNAALDH1A1TDP1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144328-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | KONRADI ANDREI W (US) | 2003-07-31 | — | — | US | claimed |
| US-7538215-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1144384-B1 | COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARM INC (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20050261293-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | WYETH | 2005-11-24 | — | — | US | disclosed |
| US-6903088-B2 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 2005-06-07 | — | — | US | disclosed |
| US-20030144328-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | KONRADI ANDREI W (US) | 2003-07-31 | — | — | US | disclosed |
| US-6479492-B1 | TREATMENT OF INFLAMMATORY DISEASES IN A MAMMALIAN PATIENT | ELAN PHARMACEUTICALS, INC. | 2002-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261293-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | KEAP1 3344/4885LMNA 3701/4885TSHR 3389/4885 |
| US-20030144328-A1 | Compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, CD4 | KEAP1 3344/4885LMNA 3701/4885TSHR 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.